http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005215793-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_015c27707dd641eb59768a705b23690b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-3873
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-58
filingDate 2005-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_664acb32b2cb51fd57f459bb7043a203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee85b08b1523042ae15e0c9f10dcfacb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e02fa881b17f88e0cc05f742d2469d78
publicationDate 2005-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2005215793-A1
titleOfInvention Amorphous 3-pyridil-1-hydroxyethyliden-1, 1-biphosphonic acid monosodium salt and process for the preparation thereof
abstract A process for the preparation of 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid monosodium salt of formula n nin an amorphous form, preferably lyophilized, and its pharmaceutical compositions are described. Said amorphous form, characterized by stability and simplicity of preparation and formulation, can be obtained by an industrially applicable lyophilization process, which comprises the steps of: a) dissolving or suspending 3-pyridyl-1-hydroxyethyliden-1,1-biphosphonic acid in an aqueous solvent, b) adding one equivalent of a base having sodium as cation c) subjecting the solution to lyophilization
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010121066-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009176913-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8076483-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7618953-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009149427-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007142332-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100812528-B1
priorityDate 2004-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7358399-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7105681-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7332603-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005142185-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7241805-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7417149-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6583287-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6897339-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5756737-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID223981211
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID141326942
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID223745467
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408351063
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4194514
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408395
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2088
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID142347884
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128171553
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394485
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128806596
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5245
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8103
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554994

Total number of triples: 50.